NanoVibronix

NAOV

Market cap $5.17M

Overview Fund Activity

6.49 USD

+0.24

3.84%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

6.47

-0.02

0.31%

1 day

3.84%

5 days

27.01%

1 month

-12.65%

3 months

-43.57%

6 months

-75.98%

Year to date

-90.48%

1 year

-91%

5 years

-99.53%

10 years

-99.93%

About: NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements.

Employees: 15

Healthcare Medical Devices

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

25% more funds holding

Funds holding: 4 [Q1] → 5 (+1) [Q2]

0.18% less ownership

Funds ownership: 0.25% [Q1] → 0.08% (-0.18%) [Q2]

73% less capital invested

Capital invested by funds: $67.5K [Q1] → $18.1K (-$49.4K) [Q2]

See Fund Rankings

Financial journalist opinion

NanoVibronix Announces U.S. Patent Granted to ENvue Medical for Real-Time Imaging Overlay in Navigation Technology

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,402,953 B2, titled “Insertion Device Positioning Guidance System and Method” on September 2, 2025 to ENvue Medical Holdings LLC (formerly ENvue Medical Holdings, Corp.), a wholly-owned subsidiary of the Company (“ENvue” or “ENv.

NanoVibronix Announces U.S. Patent Granted to ENvue Medical for Real-Time Imaging Overlay in Navigation Technology

NanoVibronix Announces Reverse Stock Split

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:05 p.m. ET on Monday, August 11, 2025. The Company's common stock will c.

NanoVibronix Announces Reverse Stock Split

NanoVibronix Announces Financing of up to $50 Million Private Placement of Preferred Stock

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices for enteral feeding, pain management and urological conditions, today announced it has entered into a definitive agreement with an institutional investor for the purchase and sale of 8,889 shares of Series H Convertible Preferred Stock (the “Preferred Stock”) with a total stated value of $8,888,889. The Preferred Stock is convertibl.

NanoVibronix Announces Financing of up to $50 Million Private Placement of Preferred Stock

NanoVibronix Announces ENvue Drive – First Intelligent Robotic Platform in Development for Bedside Feeding Tube and Vascular Line Navigation

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced the official launch of a next-generation robotic development initiative within its ENvue Medical (“ENvue” or “ENvue Medical”) division. The new platform, ENvue Drive™, is being developed to automate electromagnetic navigation for enteral and vascular access procedures at the bedside. This significant st.

NanoVibronix Announces ENvue Drive – First Intelligent Robotic Platform in Development for Bedside Feeding Tube and Vascular Line Navigation

NanoVibronix's ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems for Enteral Feeding Tube Placement

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic devices, announced today that a regional acute care hospital in upstate New York has signed an agreement to acquire two ENvue™ Navigation Systems through its ENvue Medical division (“ENvue” or “ENvue Medical”). The systems, which are currently expected to be delivered in the third quarter of 2025, will support bedside placement.

NanoVibronix's ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems for Enteral Feeding Tube Placement

ENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division (“ENvue Medical” or “ENvue”), a new U.S. patent for its pediatric feeding tube guidance system. U.S. Patent No. 12,324,632, titled “Insertion Device Positioning Guidance System,” further strengthens ENvue Medical's intellectual property portfolio and reflects the Comp.

ENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System

NanoVibronix Announces CEO Transition

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, today announced the retirement of Brian Murphy as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Doron Besser, CEO of ENvue Medical Holdings, LLC (“ENvue”), a wholly-owned subsidiary of the Company, as NanoVibronix's new CEO, also effective immediately. Mr. Murphy will remain on the C.

NanoVibronix Announces CEO Transition

NanoVibronix Responds to False Post

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (the “Company”) (NASDAQ: NAOV) confirmed that a series of posts made earlier today with respect to a $26 million registered direct offering of common stock of the Company priced at $0.45 under Nasdaq rules was falsely issued by Flash Alert and FintelAlerts. The Company has not priced and is not consummating any registered direct offering. The Company is actively investigating this misinformation and will take necessary actions to protect its sto.

NanoVibronix Responds to False Post

Major Louisiana Hospital Selects ENvue System for Feeding Tube Procedures

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division (“ENvue Medical”), that a major 420-bed acute care hospital located in the greater New Orleans area has selected the ENvue™ Navigation Platform (the “ENvue System”) to support adult feeding tube procedures. The hospital will transition from traditional blind insertion.

Major Louisiana Hospital Selects ENvue System for Feeding Tube Procedures

NanoVibronix Announces Closing of $10 Million Public Offering of Preferred Stock and Warrants

TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices, today announced the closing of its previously announced underwritten public offering of 400,000 shares of the Company's Series G Convertible Preferred Stock (“Preferred Stock”), with a par value $0.001 per share and a stated value equal to $25, and Warrants to purchase up to 4,901,982 shares of common stock, par value $0.001 per sh.

NanoVibronix Announces Closing of $10 Million Public Offering of Preferred Stock and Warrants

See News Rankings

Charts implemented using Lightweight Charts™